BCMA-Directed CAR-T Therapy in Relapsed or Refractory Multiple Myeloma
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Hematology".
Deadline for manuscript submissions: 30 September 2025 | Viewed by 161
Special Issue Editor
Interests: multiple myeloma; immuno-cellular therapies in multiple myeloma; drug-resistant multiple myeloma; drug-development in heavily treated relapse myeloma
Special Issue Information
Dear Colleagues,
Relapsed or refractory multiple myeloma poses a significant challenge in hematology. BCMA-directed CAR-T therapy has emerged as a promising treatment approach in such cases. This specialized immunotherapy targets the B-cell maturation antigen (BCMA) expressed on myeloma cells, providing a targeted and potentially curative option. However, challenges such as cytokine release syndrome and neurotoxicity persist, requiring careful patient monitoring and management. This Special Issue will explore the latest advancements, outcomes, and challenges in BCMA-directed CAR-T therapy for multiple myeloma, facilitating a deeper understanding of its potential in transforming the landscape of myeloma treatment.
We welcome original research articles and reviews focusing on mechanisms, clinical outcomes, and future directions in BCMA-directed CAR-T therapy.
I look forward to receiving your contributions.
Dr. Al-Ola A. Abdallah
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- BCMA-directed CAR-T therapy
- multiple myeloma
- relapsed multiple myeloma
- refractory multiple myeloma
- B-cell maturation antigen
- immunotherapy
- treatment outcomes
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
